Frequency of liver function disturbances in patients with acute coronary syndrome without ST segment elevation in the background of new coronavirus infection (COVID-19)

Aims: To compare the incidence of liver damage in non-ST-segment elevation acute coronary syndrome patients with and without novel coronavirus infection (COVID-19). Materials and methods: the study included 150 patients with acute coronary syndrome without ST-segment elevation who underwent successful myocardial revascularization by coronary artery stenting, which were divided into 2 groups. The COVID group included 70 patients with acute coronary syndrome without ST-segment elevation and a moderate course of new coronavirus infection detected during hospitalization by the polymerase chain reaction (nasopharyngeal and oropharyngeal swabs). The COVID-free group consisted of 80 with acute coronary syndrome without ST-segment elevation patients. Diagnosis of liver damage was carried out taking into account biochemical markers, namely: an increase in the level of transaminases, bilirubin, albumin. Results: analysis of the results showed a higher incidence of increased transaminase activity in the group of patients with new coronavirus infection: Δ Alt, ME 20.7 versus 6.0 (p = 0.004), Δ AST, ME 24.0 versus 13.0 (p = 0.04) in similar clinical groups by gender, comorbidity, cardiovascular therapy. Conclusions: the use of additional therapy included in the treatment regimen for COVID-19 infection against the background of standard ACS therapy in patients with acute coronary syndrome without ST segment elevation after percutaneous coronary interventions and new coronavirus infection (SARS-CoV-2, COVID-19) compared with patients with acute coronary syndrome without ST-segment elevation after percutaneous coronary interventions, it causes an increase in alanine aminotransferase almost 3.5 times and an increase in liver aspartate aminotransferase almost 2 times, p = 0.004 and p = 0.04, respectively.